HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited (HCG.NS) Stock Competitors & Peer Comparison
See (HCG.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCG.NS | ₹646.85 | +1.51% | 94.4B | 471.83 | ₹1.34 | N/A |
| APOLLOHOSP.BO | ₹8,026.00 | -0.63% | 1.2T | 64.04 | ₹125.26 | +0.25% |
| APOLLOHOSP.NS | ₹8,026.00 | -0.70% | 1.2T | 64.02 | ₹125.28 | +0.25% |
| MAXHEALTH.NS | ₹1,068.75 | +1.78% | 1T | 73.05 | ₹14.49 | +0.14% |
| MAXHEALTH.BO | ₹1,066.80 | +1.60% | 1T | 73.05 | ₹14.49 | +0.14% |
| FORTIS.BO | ₹960.10 | -0.32% | 726.4B | 75.70 | ₹12.71 | +0.10% |
| FORTIS.NS | ₹960.55 | -0.32% | 726.4B | 75.64 | ₹12.72 | +0.10% |
| ASTERDM.NS | ₹748.90 | -0.63% | 390.4B | 117.82 | ₹6.41 | +0.53% |
| ASTERDM.BO | ₹748.45 | -1.39% | 390.3B | 117.80 | ₹6.41 | +0.53% |
| NH.BO | ₹1,883.35 | +1.52% | 379.4B | 44.95 | ₹41.56 | +0.24% |
Stock Comparison
HCG.NS vs APOLLOHOSP.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, APOLLOHOSP.BO has a market cap of 1.2T. Regarding current trading prices, HCG.NS is priced at ₹646.85, while APOLLOHOSP.BO trades at ₹8,026.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas APOLLOHOSP.BO's P/E ratio is 64.04. In terms of profitability, HCG.NS's ROE is +0.02%, compared to APOLLOHOSP.BO's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to APOLLOHOSP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check APOLLOHOSP.BO's competition here
HCG.NS vs APOLLOHOSP.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, APOLLOHOSP.NS has a market cap of 1.2T. Regarding current trading prices, HCG.NS is priced at ₹646.85, while APOLLOHOSP.NS trades at ₹8,026.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas APOLLOHOSP.NS's P/E ratio is 64.02. In terms of profitability, HCG.NS's ROE is +0.02%, compared to APOLLOHOSP.NS's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to APOLLOHOSP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check APOLLOHOSP.NS's competition here
HCG.NS vs MAXHEALTH.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MAXHEALTH.NS has a market cap of 1T. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MAXHEALTH.NS trades at ₹1,068.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MAXHEALTH.NS's P/E ratio is 73.05. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXHEALTH.NS's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MAXHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAXHEALTH.NS's competition here
HCG.NS vs MAXHEALTH.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MAXHEALTH.BO has a market cap of 1T. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MAXHEALTH.BO trades at ₹1,066.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MAXHEALTH.BO's P/E ratio is 73.05. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXHEALTH.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MAXHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAXHEALTH.BO's competition here
HCG.NS vs FORTIS.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, FORTIS.BO has a market cap of 726.4B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while FORTIS.BO trades at ₹960.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas FORTIS.BO's P/E ratio is 75.70. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FORTIS.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to FORTIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FORTIS.BO's competition here
HCG.NS vs FORTIS.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, FORTIS.NS has a market cap of 726.4B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while FORTIS.NS trades at ₹960.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas FORTIS.NS's P/E ratio is 75.64. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FORTIS.NS's ROE of +0.11%. Regarding short-term risk, HCG.NS is more volatile compared to FORTIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FORTIS.NS's competition here
HCG.NS vs ASTERDM.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ASTERDM.NS has a market cap of 390.4B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ASTERDM.NS trades at ₹748.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ASTERDM.NS's P/E ratio is 117.82. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASTERDM.NS's ROE of +0.10%. Regarding short-term risk, HCG.NS is more volatile compared to ASTERDM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ASTERDM.NS's competition here
HCG.NS vs ASTERDM.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ASTERDM.BO has a market cap of 390.3B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ASTERDM.BO trades at ₹748.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ASTERDM.BO's P/E ratio is 117.80. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASTERDM.BO's ROE of +0.10%. Regarding short-term risk, HCG.NS is more volatile compared to ASTERDM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ASTERDM.BO's competition here
HCG.NS vs NH.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, NH.BO has a market cap of 379.4B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while NH.BO trades at ₹1,883.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas NH.BO's P/E ratio is 44.95. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NH.BO's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to NH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NH.BO's competition here
HCG.NS vs NH.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, NH.NS has a market cap of 379B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while NH.NS trades at ₹1,884.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas NH.NS's P/E ratio is 48.74. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NH.NS's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to NH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NH.NS's competition here
HCG.NS vs MEDANTA.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MEDANTA.NS has a market cap of 333.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MEDANTA.NS trades at ₹1,240.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MEDANTA.NS's P/E ratio is 60.07. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MEDANTA.NS's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MEDANTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MEDANTA.NS's competition here
HCG.NS vs MEDANTA.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MEDANTA.BO has a market cap of 333B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MEDANTA.BO trades at ₹1,235.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MEDANTA.BO's P/E ratio is 60.10. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MEDANTA.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to MEDANTA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MEDANTA.BO's competition here
HCG.NS vs KIMS.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, KIMS.BO has a market cap of 287B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while KIMS.BO trades at ₹741.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas KIMS.BO's P/E ratio is 95.14. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KIMS.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is less volatile compared to KIMS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KIMS.BO's competition here
HCG.NS vs KIMS.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, KIMS.NS has a market cap of 286.8B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while KIMS.NS trades at ₹741.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas KIMS.NS's P/E ratio is 95.07. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KIMS.NS's ROE of +0.11%. Regarding short-term risk, HCG.NS is less volatile compared to KIMS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KIMS.NS's competition here
HCG.NS vs RAINBOW.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, RAINBOW.NS has a market cap of 137.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while RAINBOW.NS trades at ₹1,350.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas RAINBOW.NS's P/E ratio is 53.52. In terms of profitability, HCG.NS's ROE is +0.02%, compared to RAINBOW.NS's ROE of +0.18%. Regarding short-term risk, HCG.NS is more volatile compared to RAINBOW.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check RAINBOW.NS's competition here
HCG.NS vs RAINBOW.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, RAINBOW.BO has a market cap of 137.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while RAINBOW.BO trades at ₹1,351.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas RAINBOW.BO's P/E ratio is 53.63. In terms of profitability, HCG.NS's ROE is +0.02%, compared to RAINBOW.BO's ROE of +0.18%. Regarding short-term risk, HCG.NS is more volatile compared to RAINBOW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check RAINBOW.BO's competition here
HCG.NS vs HCG.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, HCG.BO has a market cap of 94.4B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while HCG.BO trades at ₹646.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas HCG.BO's P/E ratio is 471.90. In terms of profitability, HCG.NS's ROE is +0.02%, compared to HCG.BO's ROE of +0.02%. Regarding short-term risk, HCG.NS is more volatile compared to HCG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check HCG.BO's competition here
HCG.NS vs JLHL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, JLHL.BO has a market cap of 88B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while JLHL.BO trades at ₹1,329.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas JLHL.BO's P/E ratio is 46.64. In terms of profitability, HCG.NS's ROE is +0.02%, compared to JLHL.BO's ROE of +0.14%. Regarding short-term risk, HCG.NS is more volatile compared to JLHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check JLHL.BO's competition here
HCG.NS vs JLHL.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, JLHL.NS has a market cap of 87.7B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while JLHL.NS trades at ₹1,328.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas JLHL.NS's P/E ratio is 46.47. In terms of profitability, HCG.NS's ROE is +0.02%, compared to JLHL.NS's ROE of +0.14%. Regarding short-term risk, HCG.NS is more volatile compared to JLHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check JLHL.NS's competition here
HCG.NS vs YATHARTH.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, YATHARTH.BO has a market cap of 77.9B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while YATHARTH.BO trades at ₹831.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas YATHARTH.BO's P/E ratio is 46.56. In terms of profitability, HCG.NS's ROE is +0.02%, compared to YATHARTH.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is less volatile compared to YATHARTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check YATHARTH.BO's competition here
HCG.NS vs YATHARTH.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, YATHARTH.NS has a market cap of 77.9B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while YATHARTH.NS trades at ₹832.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas YATHARTH.NS's P/E ratio is 46.55. In terms of profitability, HCG.NS's ROE is +0.02%, compared to YATHARTH.NS's ROE of +0.11%. Regarding short-term risk, HCG.NS is less volatile compared to YATHARTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check YATHARTH.NS's competition here
HCG.NS vs KOVAI.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, KOVAI.NS has a market cap of 73.3B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while KOVAI.NS trades at ₹5,342.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas KOVAI.NS's P/E ratio is 24.89. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KOVAI.NS's ROE of +0.22%. Regarding short-term risk, HCG.NS is less volatile compared to KOVAI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KOVAI.NS's competition here
HCG.NS vs KOVAI.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, KOVAI.BO has a market cap of 58.7B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while KOVAI.BO trades at ₹5,307.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas KOVAI.BO's P/E ratio is 24.90. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KOVAI.BO's ROE of +0.22%. Regarding short-term risk, HCG.NS is less volatile compared to KOVAI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check KOVAI.BO's competition here
HCG.NS vs ARTEMISMED.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ARTEMISMED.BO has a market cap of 43.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ARTEMISMED.BO trades at ₹275.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ARTEMISMED.BO's P/E ratio is N/A. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ARTEMISMED.BO's ROE of +0.12%. Regarding short-term risk, HCG.NS is more volatile compared to ARTEMISMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ARTEMISMED.BO's competition here
HCG.NS vs ARTEMISMED.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ARTEMISMED.NS has a market cap of 43B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ARTEMISMED.NS trades at ₹275.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ARTEMISMED.NS's P/E ratio is 118.98. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ARTEMISMED.NS's ROE of +0.12%. Regarding short-term risk, HCG.NS is less volatile compared to ARTEMISMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check ARTEMISMED.NS's competition here
HCG.NS vs INDRAMEDCO.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, INDRAMEDCO.NS has a market cap of 33B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while INDRAMEDCO.NS trades at ₹359.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas INDRAMEDCO.NS's P/E ratio is 18.07. In terms of profitability, HCG.NS's ROE is +0.02%, compared to INDRAMEDCO.NS's ROE of +0.28%. Regarding short-term risk, HCG.NS is more volatile compared to INDRAMEDCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check INDRAMEDCO.NS's competition here
HCG.NS vs INDRAMEDCO.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, INDRAMEDCO.BO has a market cap of 33B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while INDRAMEDCO.BO trades at ₹359.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas INDRAMEDCO.BO's P/E ratio is 18.06. In terms of profitability, HCG.NS's ROE is +0.02%, compared to INDRAMEDCO.BO's ROE of +0.28%. Regarding short-term risk, HCG.NS is more volatile compared to INDRAMEDCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check INDRAMEDCO.BO's competition here
HCG.NS vs DRAGARWQ.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, DRAGARWQ.BO has a market cap of 24.6B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while DRAGARWQ.BO trades at ₹5,121.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas DRAGARWQ.BO's P/E ratio is 34.50. In terms of profitability, HCG.NS's ROE is +0.02%, compared to DRAGARWQ.BO's ROE of +0.30%. Regarding short-term risk, HCG.NS is more volatile compared to DRAGARWQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check DRAGARWQ.BO's competition here
HCG.NS vs SHALBY.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, SHALBY.BO has a market cap of 17.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while SHALBY.BO trades at ₹164.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas SHALBY.BO's P/E ratio is 207.79. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SHALBY.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to SHALBY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check SHALBY.BO's competition here
HCG.NS vs SHALBY.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, SHALBY.NS has a market cap of 17.1B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while SHALBY.NS trades at ₹164.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas SHALBY.NS's P/E ratio is 206.91. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SHALBY.NS's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to SHALBY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check SHALBY.NS's competition here
HCG.NS vs KMCSHIL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, KMCSHIL.BO has a market cap of 15.3B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while KMCSHIL.BO trades at ₹95.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas KMCSHIL.BO's P/E ratio is 41.90. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KMCSHIL.BO's ROE of +0.21%. Regarding short-term risk, HCG.NS is more volatile compared to KMCSHIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check KMCSHIL.BO's competition here
HCG.NS vs GPTHEALTH.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, GPTHEALTH.NS has a market cap of 11.4B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while GPTHEALTH.NS trades at ₹142.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas GPTHEALTH.NS's P/E ratio is 28.09. In terms of profitability, HCG.NS's ROE is +0.02%, compared to GPTHEALTH.NS's ROE of +0.17%. Regarding short-term risk, HCG.NS is more volatile compared to GPTHEALTH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check GPTHEALTH.NS's competition here
HCG.NS vs MAXINDIA.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MAXINDIA.BO has a market cap of 9.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MAXINDIA.BO trades at ₹213.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MAXINDIA.BO's P/E ratio is -3560.83. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXINDIA.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is less volatile compared to MAXINDIA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check MAXINDIA.BO's competition here
HCG.NS vs MAXIND.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MAXIND.NS has a market cap of 8.3B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MAXIND.NS trades at ₹156.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MAXIND.NS's P/E ratio is -5.32. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAXIND.NS's ROE of -0.36%. Regarding short-term risk, HCG.NS is less volatile compared to MAXIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check MAXIND.NS's competition here
HCG.NS vs UNIHEALTH.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, UNIHEALTH.NS has a market cap of 7B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while UNIHEALTH.NS trades at ₹432.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas UNIHEALTH.NS's P/E ratio is 44.96. In terms of profitability, HCG.NS's ROE is +0.02%, compared to UNIHEALTH.NS's ROE of N/A. Regarding short-term risk, HCG.NS is less volatile compared to UNIHEALTH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check UNIHEALTH.NS's competition here
HCG.NS vs ASARFI.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ASARFI.BO has a market cap of 3.8B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ASARFI.BO trades at ₹195.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ASARFI.BO's P/E ratio is 23.55. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASARFI.BO's ROE of +0.13%. Regarding short-term risk, HCG.NS is less volatile compared to ASARFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check ASARFI.BO's competition here
HCG.NS vs LOTUSEYE.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, LOTUSEYE.NS has a market cap of 2.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while LOTUSEYE.NS trades at ₹108.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas LOTUSEYE.NS's P/E ratio is 327.31. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LOTUSEYE.NS's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to LOTUSEYE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check LOTUSEYE.NS's competition here
HCG.NS vs LOTUSEYE.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, LOTUSEYE.BO has a market cap of 2.2B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while LOTUSEYE.BO trades at ₹105.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas LOTUSEYE.BO's P/E ratio is 325.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LOTUSEYE.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to LOTUSEYE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check LOTUSEYE.BO's competition here
HCG.NS vs MADHAVBAUG.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MADHAVBAUG.NS has a market cap of 2.1B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MADHAVBAUG.NS trades at ₹190.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MADHAVBAUG.NS's P/E ratio is 26.01. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MADHAVBAUG.NS's ROE of N/A. Regarding short-term risk, HCG.NS is less volatile compared to MADHAVBAUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check MADHAVBAUG.NS's competition here
HCG.NS vs LEHIL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, LEHIL.BO has a market cap of 1.9B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while LEHIL.BO trades at ₹89.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas LEHIL.BO's P/E ratio is -315.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LEHIL.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to LEHIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check LEHIL.BO's competition here
HCG.NS vs AASHKA.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, AASHKA.BO has a market cap of 1.8B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while AASHKA.BO trades at ₹78.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas AASHKA.BO's P/E ratio is 75.36. In terms of profitability, HCG.NS's ROE is +0.02%, compared to AASHKA.BO's ROE of +0.02%. Regarding short-term risk, HCG.NS is less volatile compared to AASHKA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check AASHKA.BO's competition here
HCG.NS vs JSTL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, JSTL.BO has a market cap of 1.3B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while JSTL.BO trades at ₹84.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas JSTL.BO's P/E ratio is -63.86. In terms of profitability, HCG.NS's ROE is +0.02%, compared to JSTL.BO's ROE of -0.06%. Regarding short-term risk, HCG.NS is less volatile compared to JSTL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check JSTL.BO's competition here
HCG.NS vs ASPIRA.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ASPIRA.BO has a market cap of 1B. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ASPIRA.BO trades at ₹104.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ASPIRA.BO's P/E ratio is 72.14. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ASPIRA.BO's ROE of +0.11%. Regarding short-term risk, HCG.NS is less volatile compared to ASPIRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check ASPIRA.BO's competition here
HCG.NS vs FORTISMLR.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, FORTISMLR.BO has a market cap of 989.8M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while FORTISMLR.BO trades at ₹54.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas FORTISMLR.BO's P/E ratio is 21.82. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FORTISMLR.BO's ROE of +0.15%. Regarding short-term risk, HCG.NS is more volatile compared to FORTISMLR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check FORTISMLR.BO's competition here
HCG.NS vs MAITREYA.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MAITREYA.NS has a market cap of 955.8M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MAITREYA.NS trades at ₹174.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MAITREYA.NS's P/E ratio is 27.33. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MAITREYA.NS's ROE of N/A. Regarding short-term risk, HCG.NS is more volatile compared to MAITREYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check MAITREYA.NS's competition here
HCG.NS vs SANGANI.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, SANGANI.NS has a market cap of 716.4M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while SANGANI.NS trades at ₹52.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas SANGANI.NS's P/E ratio is 27.66. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SANGANI.NS's ROE of N/A. Regarding short-term risk, HCG.NS is more volatile compared to SANGANI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check SANGANI.NS's competition here
HCG.NS vs AATMAJ.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, AATMAJ.NS has a market cap of 448.6M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while AATMAJ.NS trades at ₹19.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas AATMAJ.NS's P/E ratio is 50.90. In terms of profitability, HCG.NS's ROE is +0.02%, compared to AATMAJ.NS's ROE of N/A. Regarding short-term risk, HCG.NS is more volatile compared to AATMAJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check AATMAJ.NS's competition here
HCG.NS vs MEDINOV.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, MEDINOV.BO has a market cap of 433.7M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while MEDINOV.BO trades at ₹43.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas MEDINOV.BO's P/E ratio is 20.21. In terms of profitability, HCG.NS's ROE is +0.02%, compared to MEDINOV.BO's ROE of -1.80%. Regarding short-term risk, HCG.NS is less volatile compared to MEDINOV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check MEDINOV.BO's competition here
HCG.NS vs NGIND.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, NGIND.BO has a market cap of 388.5M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while NGIND.BO trades at ₹126.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas NGIND.BO's P/E ratio is -28.01. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NGIND.BO's ROE of -0.04%. Regarding short-term risk, HCG.NS is less volatile compared to NGIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check NGIND.BO's competition here
HCG.NS vs SML.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, SML.BO has a market cap of 311.3M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while SML.BO trades at ₹73.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas SML.BO's P/E ratio is -15.60. In terms of profitability, HCG.NS's ROE is +0.02%, compared to SML.BO's ROE of -2.04%. Regarding short-term risk, HCG.NS is more volatile compared to SML.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check SML.BO's competition here
HCG.NS vs CMMHOSP.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, CMMHOSP.BO has a market cap of 287.4M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while CMMHOSP.BO trades at ₹38.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas CMMHOSP.BO's P/E ratio is -37.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to CMMHOSP.BO's ROE of +0.42%. Regarding short-term risk, HCG.NS is less volatile compared to CMMHOSP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check CMMHOSP.BO's competition here
HCG.NS vs KKSHL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, KKSHL.BO has a market cap of 286M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while KKSHL.BO trades at ₹39.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas KKSHL.BO's P/E ratio is -27.81. In terms of profitability, HCG.NS's ROE is +0.02%, compared to KKSHL.BO's ROE of -0.02%. Regarding short-term risk, HCG.NS is more volatile compared to KKSHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check KKSHL.BO's competition here
HCG.NS vs TEJNAKSH.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, TEJNAKSH.BO has a market cap of 285.2M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while TEJNAKSH.BO trades at ₹13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas TEJNAKSH.BO's P/E ratio is 20.65. In terms of profitability, HCG.NS's ROE is +0.02%, compared to TEJNAKSH.BO's ROE of +0.05%. Regarding short-term risk, HCG.NS is less volatile compared to TEJNAKSH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check TEJNAKSH.BO's competition here
HCG.NS vs NIDAN.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, NIDAN.NS has a market cap of 194.6M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while NIDAN.NS trades at ₹14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas NIDAN.NS's P/E ratio is 9.86. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NIDAN.NS's ROE of N/A. Regarding short-term risk, HCG.NS is less volatile compared to NIDAN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check NIDAN.NS's competition here
HCG.NS vs FAMILYCARE.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, FAMILYCARE.BO has a market cap of 172.8M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while FAMILYCARE.BO trades at ₹3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas FAMILYCARE.BO's P/E ratio is -3.30. In terms of profitability, HCG.NS's ROE is +0.02%, compared to FAMILYCARE.BO's ROE of -0.43%. Regarding short-term risk, HCG.NS is less volatile compared to FAMILYCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check FAMILYCARE.BO's competition here
HCG.NS vs GLHRL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, GLHRL.BO has a market cap of 133.9M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while GLHRL.BO trades at ₹13.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas GLHRL.BO's P/E ratio is -5.67. In terms of profitability, HCG.NS's ROE is +0.02%, compared to GLHRL.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to GLHRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check GLHRL.BO's competition here
HCG.NS vs ZDHJERK.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, ZDHJERK.BO has a market cap of 80M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while ZDHJERK.BO trades at ₹19.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas ZDHJERK.BO's P/E ratio is 63.00. In terms of profitability, HCG.NS's ROE is +0.02%, compared to ZDHJERK.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is more volatile compared to ZDHJERK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check ZDHJERK.BO's competition here
HCG.NS vs LOOKS.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, LOOKS.BO has a market cap of 64.2M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while LOOKS.BO trades at ₹5.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas LOOKS.BO's P/E ratio is 30.55. In terms of profitability, HCG.NS's ROE is +0.02%, compared to LOOKS.BO's ROE of +0.01%. Regarding short-term risk, HCG.NS is less volatile compared to LOOKS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check LOOKS.BO's competition here
HCG.NS vs GIANLIFE.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, GIANLIFE.BO has a market cap of 62.9M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while GIANLIFE.BO trades at ₹6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas GIANLIFE.BO's P/E ratio is -6.47. In terms of profitability, HCG.NS's ROE is +0.02%, compared to GIANLIFE.BO's ROE of -0.05%. Regarding short-term risk, HCG.NS is less volatile compared to GIANLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for HCG.NS.Check GIANLIFE.BO's competition here
HCG.NS vs DLCL.BO Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, DLCL.BO has a market cap of 42.9M. Regarding current trading prices, HCG.NS is priced at ₹646.85, while DLCL.BO trades at ₹9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas DLCL.BO's P/E ratio is 12.86. In terms of profitability, HCG.NS's ROE is +0.02%, compared to DLCL.BO's ROE of +0.04%. Regarding short-term risk, HCG.NS is more volatile compared to DLCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check DLCL.BO's competition here
HCG.NS vs NEPHROCARE-ST.NS Comparison May 2026
HCG.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCG.NS stands at 94.4B. In comparison, NEPHROCARE-ST.NS has a market cap of 0. Regarding current trading prices, HCG.NS is priced at ₹646.85, while NEPHROCARE-ST.NS trades at ₹128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCG.NS currently has a P/E ratio of 471.83, whereas NEPHROCARE-ST.NS's P/E ratio is N/A. In terms of profitability, HCG.NS's ROE is +0.02%, compared to NEPHROCARE-ST.NS's ROE of N/A. Regarding short-term risk, HCG.NS is more volatile compared to NEPHROCARE-ST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for HCG.NS.Check NEPHROCARE-ST.NS's competition here